Market closed
Aligos Therapeutics/$ALGS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Aligos Therapeutics
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
Ticker
$ALGS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
68
Website
ALGS Metrics
BasicAdvanced
$153M
Market cap
-
P/E ratio
-$12.89
EPS
2.73
Beta
-
Dividend rate
Price and volume
Market cap
$153M
Beta
2.73
52-week high
$44.39
52-week low
$6.76
Average daily volume
488K
Financial strength
Current ratio
3.809
Quick ratio
3.575
Long term debt to equity
11.444
Total debt to equity
18.231
Management effectiveness
Return on assets (TTM)
-67.32%
Return on equity (TTM)
-146.69%
Valuation
Price to revenue (TTM)
40.953
Price to book
2.73
Price to tangible book (TTM)
2.73
Price to free cash flow (TTM)
-2.886
Growth
Revenue change (TTM)
-63.40%
Earnings per share change (TTM)
-72.78%
3-year revenue growth (CAGR)
14.53%
3-year earnings per share growth (CAGR)
-46.45%
ALGS News
AllArticlesVideos
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·3 weeks ago
Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024
GlobeNewsWire·1 month ago
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Aligos Therapeutics stock?
Aligos Therapeutics (ALGS) has a market cap of $153M as of December 31, 2024.
What is the P/E ratio for Aligos Therapeutics stock?
The price to earnings (P/E) ratio for Aligos Therapeutics (ALGS) stock is 0 as of December 31, 2024.
Does Aligos Therapeutics stock pay dividends?
No, Aligos Therapeutics (ALGS) stock does not pay dividends to its shareholders as of December 31, 2024.
When is the next Aligos Therapeutics dividend payment date?
Aligos Therapeutics (ALGS) stock does not pay dividends to its shareholders.
What is the beta indicator for Aligos Therapeutics?
Aligos Therapeutics (ALGS) has a beta rating of 2.73. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.